Castrate-resistant Prostate Cancer Market Size & Growth Forecast 2027–2036, By Segments (Therapy), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Castrate-resistant Prostate Cancer Market size was valued at USD 15.4 billion in 2026 and is projected to grow at a 8.27% CAGR from 2027 to 2036, exceeding USD 34.09 billion by 2036. The industry revenue for 2027 is estimated at USD 16.47 billion.
Get more details on this report
Request Free Sample ReportCastrate-resistant Prostate Cancer Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 50.77% share driven by advanced oncology pathways, broad access to novel therapeutics, and strong hospital and clinic-based cancer care systems.
- Asia Pacific grows at 9.94% CAGR supported by improving oncology access, expanding urban healthcare infrastructure, and rising diagnosis and treatment of advanced prostate cancer.
Segment Momentum
- Hormonal therapy captured a 44.73% share in 2026, supported by established clinical use, physician familiarity, and its continued role as a foundational treatment across routine disease management pathways.
- Immunotherapy is the fastest-growing therapy segment as clinicians increasingly seek alternative treatment approaches with differentiated mechanisms for managing advanced disease beyond conventional hormonal strategies.
Market Expansion Drivers
- Rising prevalence of aging male population increasing castrate-resistant prostate cancer incidence.
- Advancements in androgen receptor inhibitors, PARP inhibitors, and immunotherapy expanding treatment uptake.
- Integration of biomarker-driven precision medicine enabling targeted therapy selection in CRPC patients.
Leading Market Participants
- Leading players in the castrate-resistant prostate cancer market include Sanofi S.A. (France), Johnson & Johnson (USA), Pfizer Inc. (USA), Astellas Pharma Inc. (Japan), Bayer AG (Germany), AstraZeneca plc (United Kingdom), Novartis AG (Switzerland), Merck & Co., Inc. (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 15.4 billion
- 2027 Estimated Market Size: USD 16.47 billion.
- Projected Market Size: USD 34.09 billion by 2036
- Growth Forecast: 8.27% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hormonal Therapy (Therapy)
- Emerging Opportunity Segment: Immunotherapy (Therapy)
Market Growth Drivers and Industry Trends
Rising prevalence of aging male population increasing castrate-resistant prostate cancer incidence
The growing elderly male population is contributing to a larger pool of patients vulnerable to advanced prostate cancer, thereby supporting the castrate-resistant prostate cancer market. Prostate cancer is strongly associated with aging, and patients whose disease progresses despite androgen deprivation therapy may eventually develop castration-resistant disease. As life expectancy increases and prostate cancer is identified and managed over longer periods, the number of patients requiring treatment for advanced disease can increase. Greater clinical attention to disease progression and long-term management is also encouraging healthcare providers to seek therapeutic options for patients whose tumors continue to progress despite conventional hormonal treatment.
Advancements in androgen receptor inhibitors, PARP inhibitors, and immunotherapy expanding treatment uptake
Ongoing advances in targeted and immune-based therapies are broadening treatment choices for patients with castration-resistant prostate cancer. The castrate-resistant prostate cancer market is benefiting from the development of androgen receptor inhibitors that interfere with hormone signaling, PARP inhibitors that exploit specific DNA repair vulnerabilities, and immunotherapy approaches designed to enhance antitumor responses. The availability of therapies addressing different biological mechanisms allows clinicians to consider treatment strategies based on disease characteristics, previous treatment exposure, and patient needs. Continued therapeutic innovation is also encouraging greater adoption of newer treatment modalities alongside established approaches for managing advanced disease.
Integration of biomarker-driven precision medicine enabling targeted therapy selection in CRPC patients
The increasing use of molecular and clinical biomarkers is improving the ability to identify patients who may benefit from specific therapies, strengthening the role of precision treatment in advanced prostate cancer care. Within the castrate-resistant prostate cancer market, biomarker testing can help identify relevant genetic alterations and biological characteristics that influence treatment sensitivity, particularly for therapies directed toward DNA repair pathways and other disease mechanisms. This approach supports more individualized treatment decisions and can reduce reliance on broad therapeutic strategies when a patient's tumor profile provides actionable information. Greater integration of diagnostic testing with therapeutic selection is also encouraging closer coordination between molecular assessment and oncology treatment planning.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of aging male population increasing castrate-resistant prostate cancer incidence | 2.40% | Low | North America, Europe | High | Near Term |
| Advancements in androgen receptor inhibitors, PARP inhibitors, and immunotherapy expanding treatment uptake | 2.10% | High | North America, Europe | High | Mid Term |
| Integration of biomarker-driven precision medicine enabling targeted therapy selection in CRPC patients | 1.70% | Moderate | North America, Asia Pacific | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the castrate-resistant prostate cancer market, reaching 50.77% in 2026. The region benefits from advanced oncology infrastructure, broad access to specialized cancer care, and strong clinical research capabilities focused on prostate cancer treatment. Growing demand for targeted and personalized therapeutic approaches is supported by sophisticated diagnostic systems and increasing adoption of treatments designed for patients whose disease progresses despite hormone-based therapy. The presence of comprehensive cancer centers, established healthcare financing systems, and extensive research activity is further strengthening access to advanced treatment options. Increasing emphasis on precision oncology and improved disease monitoring is also supporting continued development of therapies and diagnostic approaches for patients with advanced prostate cancer.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing region as healthcare infrastructure expands and awareness of advanced prostate cancer diagnosis and treatment improves. Rising healthcare expenditure, increasing access to specialist oncology services, and growing investment in modern cancer treatment facilities are broadening the addressable patient population for advanced therapies. The region is also experiencing greater adoption of precision medicine and molecular diagnostics, which can support more individualized treatment decisions for patients with complex or treatment-resistant disease. Expanding clinical research capabilities and efforts to improve cancer detection and management are further encouraging the development of advanced treatment pathways, while demographic changes and increasing attention to men’s health are strengthening long-term demand.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Evidence-Based Treatment IntegrationGermany focuses on integrating clinically validated therapies for castrate-resistant prostate cancer within established oncology networks. The country supports multidisciplinary treatment planning while encouraging the adoption of innovative therapeutics backed by strong clinical evidence.
France 🇫🇷
Coordinated Oncology NetworksFrance supports coordinated cancer care through structured referral networks and standardized treatment protocols for castrate-resistant prostate cancer. The country encourages the adoption of innovative therapies while maintaining consistent clinical management across healthcare institutions.
Italy 🇮🇹
Specialized Clinical ManagementItaly emphasizes specialist-led treatment pathways for castrate-resistant prostate cancer supported by regional oncology centers. The market continues to improve access to advanced therapies while reinforcing multidisciplinary collaboration throughout patient management.
Japan 🇯🇵
Aging Patient Care FocusJapan prioritizes treatment approaches tailored to its aging patient population in the castrate-resistant prostate cancer market. Healthcare institutions emphasize maintaining quality of life alongside expanding access to targeted therapies and improved disease monitoring.
South Korea 🇰🇷
Advanced Oncology AccessSouth Korea continues to strengthen access to innovative oncology treatments for castrate-resistant prostate cancer through specialized cancer centers. The market places increasing attention on precision medicine, biomarker-driven therapy selection, and modern diagnostic capabilities.
United States 🇺🇸
Precision Therapy AdoptionThe U.S. continues to emphasize broader adoption of advanced therapies, genomic testing, and combination treatment strategies for castrate-resistant prostate cancer. Healthcare providers increasingly prioritize personalized care pathways and participation in clinical research to support treatment optimization.
Segment Leadership and Growth Trends
Castrate-resistant Prostate Cancer Market Share (%), by Therapy, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTherapy Segment Analysis: Hormonal Therapy (Largest Segment) vs Immunotherapy (Fastest-Growing Segment)
Hormonal therapy held the largest share of the castrate-resistant prostate cancer market in 2026, accounting for 44.73% share, reflecting its established role in managing prostate cancer progression through approaches that target androgen signaling. Hormonal treatment remains an important therapeutic strategy because disease progression can continue to be influenced by androgen receptor activity even after conventional androgen deprivation. The established clinical experience surrounding hormonal approaches, together with their integration into treatment pathways for advanced disease, supports continued utilization. Ongoing refinement of treatment strategies aimed at controlling tumor progression while managing the complexities of castrate-resistant disease further reinforces the importance of hormonal therapy.
Immunotherapy is the fastest-growing therapy segment as research and treatment development increasingly explore approaches that harness or enhance the body's immune response against cancer. Interest in immunotherapeutic strategies is being strengthened by the broader movement toward more targeted and biologically informed cancer treatments, particularly for patients whose disease progresses despite conventional approaches. Advances in understanding tumor biology and immune mechanisms are creating opportunities to identify patient populations that may benefit from immune-based interventions. The increasing focus on personalized oncology and combination treatment strategies is also supporting the expanding role of immunotherapy within the castrate-resistant prostate cancer treatment landscape.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Therapy | Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy | Hormonal Therapy | Immunotherapy |
Competitive Landscape and Market Positioning
Key companies in the castrate-resistant prostate cancer market:
1. Sanofi S.A. (France)
2. Johnson & Johnson (USA)
3. Pfizer Inc. (USA)
4. Astellas Pharma Inc. (Japan)
5. Bayer AG (Germany)
6. AstraZeneca plc (United Kingdom)
7. Novartis AG (Switzerland)
8. Merck & Co. Inc. (USA)
9. Takeda Pharmaceutical Company Limited (Japan)
10. Amgen Inc. (USA)
The castrate-resistant prostate cancer market is advancing through continuous clinical research focused on improving treatment effectiveness and patient survival outcomes. Increasing exploration of combination therapies, targeted drug delivery systems, and precision oncology approaches is reshaping therapeutic development strategies. Growing emphasis on personalized treatment pathways is also contributing to innovation within advanced cancer care solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Sanofi S.A. (France) | |||||||
| Johnson & Johnson (USA) | |||||||
| Pfizer Inc. (USA) | |||||||
| Astellas Pharma Inc. (Japan) | |||||||
| Bayer AG (Germany) | |||||||
| AstraZeneca plc (United Kingdom) | |||||||
| Novartis AG (Switzerland) | |||||||
| Merck & Co. Inc. (USA) | |||||||
| Takeda Pharmaceutical Company Limited (Japan) | |||||||
| Amgen Inc. (USA). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Amgen | May-26 | Amgen initiated a Phase 3 clinical trial for xaluritamig, targeting patients with androgen receptor pathway inhibitor- and taxane-refractory mCRPC. This trial represents a critical effort to provide an alternative therapy for a highly resistant patient population, potentially establishing a new standard of care in the advanced prostate cancer treatment landscape. |
| Halda Therapeutics | May-26 | Halda Therapeutics reported positive early clinical activity for its RIPTAC-based “hold and kill” therapy in treatment-resistant prostate cancer. These results provide critical initial validation of a novel mechanism of action, offering a potential new therapeutic avenue for heavily pretreated patients who have exhausted standard clinical options. |
| FL-020 Developer | May-26 | Preliminary Phase 1 ProTACT data confirmed the safety and anti-tumor activity of [225Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in mCRPC patients. This development advances the clinical proof-of-concept for targeted radiopharmaceuticals, reinforcing the potential for alpha-emitting therapies to deliver meaningful clinical benefits in challenging, metastatic disease settings. |
| Clarity Pharmaceuticals | Apr-26 | Clarity Pharmaceuticals received FDA Fast Track Designation for 67Cu-SAR-bisPSMA, supported by initial data from the SECuRE trial. This regulatory milestone serves as a major catalyst for the program, potentially accelerating the clinical development pathway and regulatory review process for this targeted radiopharmaceutical candidate in the metastatic castration-resistant prostate cancer market. |
| Syncromune | Apr-26 | Syncromune was granted FDA Fast Track Designation for its immunotherapy candidate, SYNC-T SV-102, for mCRPC. This designation highlights the potential of the company’s unique treatment mechanism and provides a framework for accelerated development, reflecting the urgent need for novel immunotherapeutic approaches to treat advanced, treatment-resistant prostate cancer. |
| EDAP TMS SA | Apr-26 | EDAP TMS SA and Cortechs.ai achieved the first clinical application of OnQ Prostate imaging integrated with the Focal One Robotic HIFU platform. This technical integration advances MRI-guided focal therapy by enhancing lesion localization and procedural precision, representing a significant technological evolution in non-invasive, precision-targeted treatment options for prostate cancer care. |
| AstraZeneca | Jun-24 | AstraZeneca acquired Fusion Pharmaceuticals, securing the lead radioconjugate candidate FPI-2265 for mCRPC treatment. This acquisition significantly bolsters the firm’s oncology pipeline and R&D infrastructure in radiopharmaceuticals, positioning AstraZeneca to compete more effectively in the high-growth targeted radioconjugate segment and expanding its global footprint in innovative cancer therapeutics. |
| Novartis | May-24 | Novartis acquired Mariana Oncology to strengthen its radioligand therapy (RLT) pipeline. This strategic integration combines Mariana’s preclinical innovation with Novartis’ established RLT infrastructure, reinforcing the company’s leadership in targeted radiotherapy and accelerating the development of next-generation modalities designed to address significant unmet clinical needs in advanced prostate cancer. |
| Johnson & Johnson | Mar-24 | Johnson & Johnson completed the acquisition of Ambrx Biopharma, gaining access to a proprietary synthetic biology platform for antibody-drug conjugates (ADCs). The acquisition specifically enhances the company’s oncology portfolio with ARX517, a PSMA-targeting ADC for mCRPC, signaling a strategic commitment to advanced precision medicine and diversified therapeutic options for treatment-resistant patient populations. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Castrate-resistant Prostate Cancer Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Line of Therapy | First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy |
| Biomarker Status | Biomarker-Positive, Biomarker-Negative, Biomarker-Unknown |
| Care Setting | Hospitals, Specialty Cancer Centers, Ambulatory Care Settings, Home-Based Care |
Castrate-resistant Prostate Cancer Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Emerging Therapeutic Modality Assessment |
|
| Treatment Sequencing and Clinical Practice Assessment |
|
| Biomarker Testing Adoption Landscape |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of castrate-resistant prostate cancer?
What is the expected industry size of castrate-resistant prostate cancer by 2036?
How are therapeutic advancements reshaping treatment adoption in the castrate-resistant prostate cancer market?
How is biomarker-driven precision medicine influencing the castrate-resistant prostate cancer market?
Why does hormonal therapy remain the leading treatment in the castrate-resistant prostate cancer market?
How is immunotherapy influencing growth in the castrate-resistant prostate cancer market?
Why does North America hold the leading share in the castrate-resistant prostate cancer market?
What is driving faster growth in Asia Pacific for castrate-resistant prostate cancer treatments?
Which organizations are considered leaders in the castrate-resistant prostate cancer landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization